Second-line HIV treatment in ugandan children: Favorable outcomes and no protease inhibitor resistance

Ragna S. Boerma, Cissy Kityo, T. Sonia Boender, Elizabeth Kaudha, Joshua Kayiwa, Victor Musiime, Andrew Mukuye, Mary Kiconco, Immaculate Nankya, Lilian Nakatudde, Peter N. Mugyenyi, Michael Boele van Hensbroek, Tobias F.Rinke de Wit, Kim C.E. Sigaloff, Job C.J. Calis

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Data on pediatric second-line antiretroviral treatment (ART) outcomes are scarce, but essential to evaluate second-line and design third-line regimens. Methods: Children ≤ 12 years switching to second-line ART containing a protease inhibitor (PI) in Uganda were followed for 24 months. Viral load (VL) was determined at switch to second-line and every 6 months thereafter; genotypic resistance testing was done if VL ≥ 1000 cps/ml. Results: 60 children were included in the analysis; all had ≥ 1 drug resistance mutations at switch. Twelve children (20.0%) experienced treatment failure; no PI mutations were detected. Sub-optimal adherence and underweight were associated with treatment failureConclusions: No PI mutations occurred in children failing second-line ART, which is reassuring as pediatric third-line is not routinely available in these settings. Poor adherence rather than HIV drug resistance is likely to be the main mechanism for treatment failure and should receive close attention in children on second-line ART.

Original languageEnglish
Pages (from-to)135-143
Number of pages9
JournalJournal of tropical pediatrics
Volume63
Issue number2
Publication statusPublished - 1 Jan 2017

Cite this

Boerma, R. S., Kityo, C., Boender, T. S., Kaudha, E., Kayiwa, J., Musiime, V., ... Calis, J. C. J. (2017). Second-line HIV treatment in ugandan children: Favorable outcomes and no protease inhibitor resistance. Journal of tropical pediatrics, 63(2), 135-143.
Boerma, Ragna S. ; Kityo, Cissy ; Boender, T. Sonia ; Kaudha, Elizabeth ; Kayiwa, Joshua ; Musiime, Victor ; Mukuye, Andrew ; Kiconco, Mary ; Nankya, Immaculate ; Nakatudde, Lilian ; Mugyenyi, Peter N. ; van Hensbroek, Michael Boele ; de Wit, Tobias F.Rinke ; Sigaloff, Kim C.E. ; Calis, Job C.J. / Second-line HIV treatment in ugandan children : Favorable outcomes and no protease inhibitor resistance. In: Journal of tropical pediatrics. 2017 ; Vol. 63, No. 2. pp. 135-143.
@article{5b793f57fe1b4ca093bf81383e920a0d,
title = "Second-line HIV treatment in ugandan children: Favorable outcomes and no protease inhibitor resistance",
abstract = "Background: Data on pediatric second-line antiretroviral treatment (ART) outcomes are scarce, but essential to evaluate second-line and design third-line regimens. Methods: Children ≤ 12 years switching to second-line ART containing a protease inhibitor (PI) in Uganda were followed for 24 months. Viral load (VL) was determined at switch to second-line and every 6 months thereafter; genotypic resistance testing was done if VL ≥ 1000 cps/ml. Results: 60 children were included in the analysis; all had ≥ 1 drug resistance mutations at switch. Twelve children (20.0{\%}) experienced treatment failure; no PI mutations were detected. Sub-optimal adherence and underweight were associated with treatment failureConclusions: No PI mutations occurred in children failing second-line ART, which is reassuring as pediatric third-line is not routinely available in these settings. Poor adherence rather than HIV drug resistance is likely to be the main mechanism for treatment failure and should receive close attention in children on second-line ART.",
keywords = "Antiretroviral treatment, Genotypic resistance testing, HIV drug resistance, HIV-1, Second-line",
author = "Boerma, {Ragna S.} and Cissy Kityo and Boender, {T. Sonia} and Elizabeth Kaudha and Joshua Kayiwa and Victor Musiime and Andrew Mukuye and Mary Kiconco and Immaculate Nankya and Lilian Nakatudde and Mugyenyi, {Peter N.} and {van Hensbroek}, {Michael Boele} and {de Wit}, {Tobias F.Rinke} and Sigaloff, {Kim C.E.} and Calis, {Job C.J.}",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "63",
pages = "135--143",
journal = "Journal of tropical pediatrics",
issn = "0142-6338",
publisher = "Oxford University Press",
number = "2",

}

Boerma, RS, Kityo, C, Boender, TS, Kaudha, E, Kayiwa, J, Musiime, V, Mukuye, A, Kiconco, M, Nankya, I, Nakatudde, L, Mugyenyi, PN, van Hensbroek, MB, de Wit, TFR, Sigaloff, KCE & Calis, JCJ 2017, 'Second-line HIV treatment in ugandan children: Favorable outcomes and no protease inhibitor resistance' Journal of tropical pediatrics, vol. 63, no. 2, pp. 135-143.

Second-line HIV treatment in ugandan children : Favorable outcomes and no protease inhibitor resistance. / Boerma, Ragna S.; Kityo, Cissy; Boender, T. Sonia; Kaudha, Elizabeth; Kayiwa, Joshua; Musiime, Victor; Mukuye, Andrew; Kiconco, Mary; Nankya, Immaculate; Nakatudde, Lilian; Mugyenyi, Peter N.; van Hensbroek, Michael Boele; de Wit, Tobias F.Rinke; Sigaloff, Kim C.E.; Calis, Job C.J.

In: Journal of tropical pediatrics, Vol. 63, No. 2, 01.01.2017, p. 135-143.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Second-line HIV treatment in ugandan children

T2 - Favorable outcomes and no protease inhibitor resistance

AU - Boerma, Ragna S.

AU - Kityo, Cissy

AU - Boender, T. Sonia

AU - Kaudha, Elizabeth

AU - Kayiwa, Joshua

AU - Musiime, Victor

AU - Mukuye, Andrew

AU - Kiconco, Mary

AU - Nankya, Immaculate

AU - Nakatudde, Lilian

AU - Mugyenyi, Peter N.

AU - van Hensbroek, Michael Boele

AU - de Wit, Tobias F.Rinke

AU - Sigaloff, Kim C.E.

AU - Calis, Job C.J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Data on pediatric second-line antiretroviral treatment (ART) outcomes are scarce, but essential to evaluate second-line and design third-line regimens. Methods: Children ≤ 12 years switching to second-line ART containing a protease inhibitor (PI) in Uganda were followed for 24 months. Viral load (VL) was determined at switch to second-line and every 6 months thereafter; genotypic resistance testing was done if VL ≥ 1000 cps/ml. Results: 60 children were included in the analysis; all had ≥ 1 drug resistance mutations at switch. Twelve children (20.0%) experienced treatment failure; no PI mutations were detected. Sub-optimal adherence and underweight were associated with treatment failureConclusions: No PI mutations occurred in children failing second-line ART, which is reassuring as pediatric third-line is not routinely available in these settings. Poor adherence rather than HIV drug resistance is likely to be the main mechanism for treatment failure and should receive close attention in children on second-line ART.

AB - Background: Data on pediatric second-line antiretroviral treatment (ART) outcomes are scarce, but essential to evaluate second-line and design third-line regimens. Methods: Children ≤ 12 years switching to second-line ART containing a protease inhibitor (PI) in Uganda were followed for 24 months. Viral load (VL) was determined at switch to second-line and every 6 months thereafter; genotypic resistance testing was done if VL ≥ 1000 cps/ml. Results: 60 children were included in the analysis; all had ≥ 1 drug resistance mutations at switch. Twelve children (20.0%) experienced treatment failure; no PI mutations were detected. Sub-optimal adherence and underweight were associated with treatment failureConclusions: No PI mutations occurred in children failing second-line ART, which is reassuring as pediatric third-line is not routinely available in these settings. Poor adherence rather than HIV drug resistance is likely to be the main mechanism for treatment failure and should receive close attention in children on second-line ART.

KW - Antiretroviral treatment

KW - Genotypic resistance testing

KW - HIV drug resistance

KW - HIV-1

KW - Second-line

UR - http://www.scopus.com/inward/record.url?scp=85019006036&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 135

EP - 143

JO - Journal of tropical pediatrics

JF - Journal of tropical pediatrics

SN - 0142-6338

IS - 2

ER -

Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V et al. Second-line HIV treatment in ugandan children: Favorable outcomes and no protease inhibitor resistance. Journal of tropical pediatrics. 2017 Jan 1;63(2):135-143.